Spec. MD.


Liv Bona Dea Hospital Bakü
Medical Oncology
Areas of Interests
    • Cancer diagnosis and treatment
    • Cytotoxic chemotherapy
    • Hormone therapy
    • Target treatment (smart drug treatment)
    • Immunotherapy

  • 2004-2010 Azerbaijan Medical University
  • 2014-2019, Istanbul University, Istanbul Faculty of Medicine, internal medicine specialist
  • 2019-2022 Istanbul Medipol Mega University Hospital oncology subspecialty


Experience: Internal medicine specialist for 5 years

Oncology subspecialty for 3 years

Specialization Thesis:

Evaluation of Clinical, Laboratory Findings and Treatment Results of Patients Followed with the Diagnosis of Essential Thrombocythemia


  • Randomized, double-blind, phase 3 study of platinum-based chemotherapy with or without INCMGA00012 in first-line metastatic squamous and non-squamous non-small cell lung cancer
  • Phase III, Double-Blind, Placebo-Controlled Randomized Study Evaluating the Combination of Ipatasertib, Atezolizumab, and Paclitaxel in Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (C041101 IPATUNITY 170 MINISTRY CODE: 19-ROC-05)
  • Titled “Phase 3 Randomized Study Comparing Amivantamab and Lazertinib Combination Therapy with Osimertinib and Lazertinib Alone Treatment as First-Line Treatment in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Mutation” and numbered 73841937NSC3003 (Ministry code: 202003090)
  • Titled “Randomized, Open-Label Phase 3 Study Comparing Amivantamab and Carboplatin Pemetrexed Combination Therapy with Carboplatin Pemetrexed Treatment in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20ins Mutation” and numbered 61186372NSC3001 (Ministry code: 202003118).
  • Randomized, multicenter, double-blind phase 3 study comparing letrozole plus palbociclib with SAR439859 plus palbociclib in patients who had not received systemic anti-cancer therapy for ER (+), HER2 (-) advanced breast cancer - AMEERA-5, EFC15935” and “EFC15935 (Ministry code: 202003120)”
  • Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Progression-Free Locally Advanced, Non-Resectable Stage III Non-Small Cell Lung Cancer After Concurrent Platinum-Based Chemoradiation (Skyscraper-03), GO41854, SKYSCAPER03
  • Phase III, randomized, double-blind, placebo-controlled study evaluating atezolizumab plus carboplatin and etoposide with or without tiragolumab (anti-Tigit antibody) in patients with untreated extensive-stage small cell lung cancer, go41767 skyscraper02
  • Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy, with or without Olaparib (MK7339) Compared to Concurrent Chemoradiation Therapy Alone in Newly Diagnosed, Treatment-Naive, Limited-Stage Small Cell Lung Cancer (SE-SCLC) Subjects Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Pembrolizumab” and “MK7339-013 (Ministry code: 202003108)
  • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Gdc9545 and Palbociclib Compared to the Combination of Letrozole and Palbociclib in Patients with Estrogen Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer, BO41843, PersevERA
  • A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-Based Chemotherapy in Completely Resected Stage II-III Non-Small Cell Lung Cancer (MeRmaiD-1)” and “D910LC00001(Mermaid) -1) (Ministry code: 202003050)
  • Phase 3, Randomized, Double-Blind Study of Pembrolizumab Compared to Placebo with or without Radiotherapy in Combination with Adjuvant Chemotherapy for the Post-Surgical Treatment of Newly Diagnosed High-Risk Endometrial Cancer with Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)” and “MK3475-B21 (Ministry code: 202003126)
  • PIK3CA Registry Study: A descriptive study on PIK3CA mutations in patients with HR+/Her2- advanced breast cancer” and “CBYL719C2401 (Ministry code: -)
  • “Randomized, Controlled, Multicenter, 3-Arm Phase III Study Investigating Neoadjuvant Osimertib given as Monotherapy or in Combination with Chemotherapy versus Standard Chemotherapy Alone in Epidermal Growth Factor Receptor Mutation Positive Resectable Non-Small Cell Lung Cancer Patients (NeoADAURA)” and “D516AC00001(NeoADAURA) (Ministry code: 202003046)
  • Phase 3 Study of Pembrolizumab (MK-3475) with or without Olaparib Following Concurrent Chemoradiotherapy, Compared to Durvalumab, in Subjects with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)” and “MK7339 -012 (Ministry code: 2020030119)”
  • Randomized, Double-Blind, Multiplex to compare the clinical efficacy and safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer (MSLCL). Centered, Phase III Study {HLX10-005-SCLC301 (Ministry code: 19-PRX-26)}
  • Chemotherapy (carboplatin-nanoparticle albumin-bound (nab)-paclitaxel) versus chemotherapy (carboplatin-nab-paclitaxel) + HLX10 (recombinant anti-seizure) as first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). -P
  • Turkish Medical Oncology Society
  • ESMO: European Society of Oncology
  • ASCO: American Society of Oncology
Ask our Experts!
You can contact with our experts for your questions!